Compare ELTX & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | FORA |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 69.4M |
| IPO Year | N/A | N/A |
| Metric | ELTX | FORA |
|---|---|---|
| Price | $8.14 | $2.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 106.6K | 29.3K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $28,106,911.00 |
| Revenue This Year | N/A | $47.82 |
| Revenue Next Year | N/A | $10.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 37.47 |
| 52 Week Low | $4.60 | $1.64 |
| 52 Week High | $12.62 | $4.03 |
| Indicator | ELTX | FORA |
|---|---|---|
| Relative Strength Index (RSI) | 44.68 | 41.72 |
| Support Level | $7.89 | $2.11 |
| Resistance Level | $8.30 | $2.18 |
| Average True Range (ATR) | 0.57 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 38.38 | 31.25 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.